Earlier this month, the U.S. Food and Drug Administration (FDA) changed the safety labeling for Addyi (flibanserin), a medication used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Women with this type of HSDD have little or no interest in sex, even though they have had a satisfying libido in the […]
HSDD, Fecal Incontinence Linked to Aromatase Inhibitors
Aromatase inhibitors (AIs) are associated with hypoactive sexual desire disorder (HSDD) and fecal incontinence in breast cancer survivors ten years after diagnosis, according to a recent Journal of Sexual Medicine study.
FDA Panel Conditionally Recommends Flibanserin Approval
On June 4, an advisory panel to the U.S. Food and Drug Administration (FDA) voted 18-6 in favor of recommending the approval of flibanserin for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in the United States.
Flibanserin, HSDD, and the BEGONIA Trial
Results of a recent drug trial suggest that premenopausal women with hypoactive sexual desire disorder (HSDD) may benefit from a daily dose of flibanserin, a medication designed to improve sexual desire.